Innate Pharma (IPHA) Gains from Investment Securities (2023 - 2024)
Innate Pharma (IPHA) posted quarterly Gains from Investment Securities of -$1.1 million for Q2 2024, up 4.98% year-on-year from -$1.1 million in Q3 2023, and up 4.98% on a QoQ basis from -$1.2 million in Q2 2023.
Innate Pharma (IPHA) Gains from Investment Securities (2023 - 2024) Analysis & Trends
Innate Pharma (IPHA) has reported Gains from Investment Securities for 2 consecutive years, with -$1.1 million the latest figure, recorded in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn |
| 10 | Innate Pharma | 160.52 Mn | 160.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.13 Mn |
| Jun 30, 2023 | -1.19 Mn |
| Jun 30, 2023 | -1.19 Mn |